Available in Argentina, Chile, Spain
This study will assess the efficacy and safety of T-DXd compared with Ram + PTX in
participants with HER2-positive (defined as immunohistochemistry [IHC] 3+ or IHC 2+/in situ
hybridization [ISH]+) gastric or GEJ adenocarcinoma (based on [American Society of Clinical
Oncology (ASCO) College of American Pathologists (CAP) guidelines who have progressed on or
after a trastuzumab-containing regimen and have not received any additional systemic therapy.
Participants will be randomized 1:1 to either T-DXd or Ram + PTX treatment. The primary
objective will assess overall survival. Secondary objectives will further assess
progression-free survival, objective response rate, duration of response, disease control
rate, safety, pharmacokinetics, and immunogenicity of T-DXd.
12Research sites
490Patients around the world